Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Ludovic Bourre

Citation

Annals of Oncology (2020) 31 (suppl_1): S17-S18. 10.1016/annonc/annonc81

Authors

L. Bourre, X. Xu, L. Shang, L. Wang, C. Li, Y. Liu, P. Han, Z. Sun, Y. Qu, L. Zhang, B. Chen, D. Ouyang, Y. Huang, H. Li

Author affiliations

  • Crown Bioscience Inc., 92127 - San Diego/US
More

Resources

Patient-derived xenograft (PDX), a cancer stem cell (CSC)-derived in vivo model, is an accepted model of choice for preclinical and translational research due to its proven predictive power. Patient-derived cancer organoids (PDOs), also CSC-derived 3D culture of carcinoma with defined structures, harbor carcinoma’s multicellular components and mimics cancer lesion structures/heterogeneity, both genomicly and histopathologically. PDO was first described by Hans Clevers Lab and proven to be a predictive model for preclinical research, similar to PDX.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings